M1 Kliniken AG Receives Positive Review on Preliminary 2023 Results from First Berlin Equity Research

First Berlin Equity Research GmbH has published an update on M1 Kliniken AG, confirming a stable "BUY" rating with a target price of €18. According to the analyst Ellis Acklin, M1 Kliniken showcased strong preliminary results for 2023, especially within its Beauty segment. The German clinic network led these results with a notable €56 million in sales and a robust 28% EBIT margin. Although the international clinics just missed achieving a positive EBIT, recording €-0.2 million compared to €-2.4 million in 2022, there's a visible improvement.

Additionally, in 2023, M1 Kliniken expanded its footprint by opening four new beauty centers across three countries, with two more opened this year, raising the total to 60 centers. Plans for further openings remain on schedule. Given these developments, First Berlin has increased its forecasts to reflect the enhanced performance in the Beauty segment, maintaining an optimistic outlook for M1 Kliniken AG.